Source: International Congress 2019 – Clinical approach to asthma management
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Swaminathan (New York, United States of America), A. Gerber (Denver, United States of America), K. Qirko (New York, United States of America), N. Wysham (Vancouver, United States of America), E. Corcoran (Portland, United States of America), T. Smith (Louisville, United States of America). A digital therapy for proactively managing exacerbations and delivering therapeutic benefit to patients with moderate to severe asthma. 2724

Member's Comments

No comment yet.

Related content which might interest you: Identifying patients with severe asthma that will be benefit from biological therapy Source: Virtual Congress 2020 – Rethinking asthma Year: 2020 The use of omalizumab in the management of severe chronic paediatric asthma Source: Annual Congress 2008 - Drug therapy and assessment of control in childhood asthma Year: 2008 Is CRP-guided antibiotic treatment a safe way to reduce antibiotic use in severe hospitalised patients with exacerbations of COPD? Source: Eur Respir J, 54 (4) 1901597; 10.1183/13993003.01597-2019 Year: 2019 Is CRP-guided antibiotic treatment a safe way to reduce antibiotic use in severe hospitalised patients with exacerbations of COPD? Source: Eur Respir J, 54 (4) 1901405; 10.1183/13993003.01405-2019 Year: 2019 Combination asthma medication and healthcare use in severe or difficult-to-treat asthma Source: Eur Respir J 2004; 24: Suppl. 48, 131s Year: 2004 The cost-efficacy of combined anti-inflammatory therapy in the treatment of children in severe persistent asthma Source: Eur Respir J 2003; 22: Suppl. 45, 134s Year: 2003 Can we use a biomarker to guide antibiotic treatment in severe COPD exacerbations? Source: Breathe, 15 (4) 353; 10.1183/20734735.0257-2019 Year: 2019 Evaluating the efficacy of omalizumab in severe persistent asthma patients Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017 Cost implications for the introduction of omalizumab in to the management of severe chronic asthma in children Source: Eur Respir J 2006; 28: Suppl. 50, 481s Year: 2006 Severe asthma and biologic therapies during COVID-19: supporting patients care with home administration of mepolizumab and omalizumab Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021 Triple therapy for all patients with severe symptomatic COPD at risk of exacerbations Source: Eur Respir J, 53 (4) 1900147; 10.1183/13993003.00147-2019 Year: 2019 Pharmacological strategies for self-management of asthma exacerbations Source: Eur Respir J 2006; 28: 182-199 Year: 2006 The prevalence of severe asthma in specialist care –identifying eligible candidates for biological therapies Source: International Congress 2017 – Clinical points to ponder in asthma Year: 2017 Use of relievers in patients with severe asthma on biologic therapy –a multidisciplinary approach Source: Virtual Congress 2020 – Challenges and updates in nursing care around the world Year: 2020 Physicians judge add-on omalizumab therapy as an effective treatment for patients with severe persistent allergic asthma: a pooled analysis Source: Eur Respir J 2005; 26: Suppl. 49, 49s Year: 2005 Endotypes of severe allergic asthma patients who clinically benefit from Anti-IgE therapy Source: International Congress 2018 – Studying novel biomarkers in asthma and COPD Year: 2018 Two therapy option in patients with uncontrolled asthma Source: International Congress 2018 – Physiological and biological insights in asthma Year: 2018 Effects of an eHealth intervention promoting correct use of medication in patients with asthma and chronic obstructive pulmonary disease Source: Virtual Congress 2021 – Remote monitoring of respiratory patients Year: 2021 Which patients with COPD can potentially benefit from prophylactic use of antibiotics? Source: Annual Congress 2007 - Different aspects of COPD exacerbations Year: 2007 Feasibility and benefits of an innovative airway clearance device in COPD patients hospitalized for acute exacerbation Source: Virtual Congress 2020 – New insights into determinants of patient-reported outcomes in chronic respiratory diseases Year: 2020